Therapeutics for mitochondrial diseases
Location: United States, Massachusetts, Waltham
Total raised: $72.5M
Investors 4
| Date | Name | Website |
| 08.11.2023 | ARCH Ventu... | archventur... |
| - | GU Venture... | guventures... |
| - | Eir Ventur... | eirventure... |
| 18.05.2023 | Cambridge ... | cic.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.09.2022 | Series A | $72.5M | - |
Mentions in press and media 16
| Date | Title | Description |
| 14.07.2025 | Pretzel Therapeutics Receives Investment from Mito Fund | Pretzel Therapeutics, a Boston, MA-based company biotechnology company developing treatments for POLG and mtDNA depletion related mitochondrial diseases, received an investment from Mito Funds. The amount of the deal was not disclosed. The ... |
| 26.09.2024 | ARCH Venture Partners Announces New Fund to Create the Next Generation of Biotech Companies | - |
| 20.09.2022 | Pretzel Therapeutics Launches With $72.5M to Pioneer Mitochondrial Therapies | What You Should Know: Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondri... |
| 14.09.2022 | Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies | Company to leverage expertise in mitochondrial biology to advance novel treatments for both rare and common diseases Pretzel founded by leading academic experts in mitochondrial biology and backed by world-class investor syndicate Platfor... |
| 14.09.2022 | Eir Ventures portfolio company, Pretzel Therapeutics, announces USD 72,5M series A financing | - |
| 12.09.2022 | Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies | Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies Company to leverage expertise in mitochondrial biology to advance novel treatments for both rare and common diseases Pretzel founded by l... |
| 12.09.2022 | Pretzel Therapeutics, eyeing diseases caused by broken mitochondria, launches with $72.5 million | In the life sciences industry, where company names derived from “biology” or “genetics” are a dime a dozen, it helps to have a brand that stands out. Pretzel Therapeutics is one of this year’s more creative gambits, launching Monday with $7... |
| 12.09.2022 | Pretzel Therapeutics Snares $72.5M Series A | WALTHAM, MA, Pretzel Therapeutics, a biotechnology company, launched with a $72.5 million Series A financing. >> Click here for more funding data on Pretzel Therapeutics >> To export Pretzel Therapeutics funding data to PDF ... |
| 28.04.2022 | Life science pioneers Epitopea and Pretzel Therapeutics backed by Cambridge Innovation Capital | Life science pioneers Epitopea and Pretzel Therapeutics backed by Cambridge Innovation Capital Business Weekly article | By Tony Quested Cambridge Innovation Capital, which earlier this week rolled out a second fund worth $300 million, is i... |
| 27.04.2022 | £225m raised for Cambridge Innovation Capital’s Fund II | £225m raised for Cambridge Innovation Capital’s Fund II Cambridge Independent article | By Mike Scialom Cambridge Innovation Capital (CIC), the venture capital investor focused on building world-leading deeptech and life sciences businesses... |
Show more